Company news

Theravance Biopharma, Inc. news in 2022

Theravance Biopharma, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Theravance Biopharma, Inc. Announces Final Results of Tender Offer

November 21, 2022

Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer

November 17, 2022

Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

November 6, 2022

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

November 1, 2022

Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022

October 30, 2022

Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System

October 24, 2022

Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares

September 27, 2022

Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program

September 18, 2022

Theravance Biopharma to Present at Upcoming Investor Conferences

September 5, 2022

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

July 27, 2022

Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023

July 25, 2022

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

July 12, 2022

Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022

Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022

May 1, 2022

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)

April 3, 2022

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 22, 2022

Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

February 8, 2022

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

January 9, 2022

Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Calls in 2022

Decks in 2022